Enjoy complimentary customisation on priority with our Enterprise License!
The global upper respiratory tract infection treatment market size is estimated to grow by USD 2,661.15 million at a CAGR of 4.21% between 2023 and 2028.
Top players in the market would be encouraged to concentrate on developing drugs that treat upper tract infections given the high prevalence of these infections. In the pipeline, a number of late-stage molecules are likely to be launched over the next few years. For instance, Emergo Therapeutics is developing norketotifen, an antagonist of the histamine H1 receptor and mast stabilizer, to treat allergic rhinitis. The drug is currently in a Phase II clinical trial. Hence, such a favorable drug pipeline will boost the growth of the market growth during the forecast period.
Technavio has segmented the market into Type, Distribution Channel, and Application
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018 to 2022, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
The market share growth by the antibiotics segment will be significant during the forecast period. This segment contains antibiotics such as azithromycin, amoxicillin, doxycycline, clarithromycin, erythromycin, and VIBRAMYCIN. The comfortable availability of antibiotics to treat upper respiratory tract infections and their signs will drive the market growth. Upper respiratory tract infections are caused by bacteria such as Streptococcus pneumoniae, Chlamydia pneumonia.
Get a glance at the market contribution of various segments View a PDF Sample
The antibiotics segment was valued at USD 5,818.83 million in 2018. Antibiotics are used to treat various symptoms, such as pneumonia, influenza, and other respiratory tract infections. Furthermore, the widespread prevalence of respiratory tract infections across the globe, the increasing resistance of bacteria to non-antibiotic treatments, and the growing awareness among healthcare professionals about appropriate antibiotic usage and the development of new and more potent antibiotics will drive the growth of the antibiotics segment of the market during the forecast period.
Hospital pharmacies work closely with suppliers and pharmaceutical companies to purchase medications needed to treat the upper respiratory tract. These drugs are then stored in pharmaceutical warehouses. Inventory management systems help monitor stock levels and ensure that an adequate supply of respiratory medications is available. Moreover, hospital pharmacies often provide patient education on how to use respiratory medications correctly. This education contributes to better patient adherence and more effective drug distribution. These factors will contribute to the growth of the hospital pharmacies segment, which will drive the growth of the market in focus during the forecast period.
The market has a well-established offline distribution channel that includes various types of retail pharmacy stores, such as drugstores, supermarkets, hypermarkets, and convenience stores. The primary mode of distribution of onychomycosis drugs is through these retail pharmacies, which have a wide geographical presence and are easily accessible to consumers. Moreover, the increasing number of pharmacy stores, supermarkets, and hypermarkets, the ease of availability of OTC/antibiotics drugs across platforms, and the easy accessibility to outlets are estimated to drive the growth of the retail pharmacies segment of the global upper respiratory tract infection treatment market during the forecast period
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 47% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The North American market is dominated by the US and is driven by increasing rates of upper respiratory tract infection therapeutic. The growing elderly population requires more respiratory drugs and medical services. North America, especially the US and Canada, has an aging population, increasing the incidence of respiratory diseases.
Furthermore, the presence of specialized respiratory care centers and clinics across North America ensures comprehensive care for patients with respiratory conditions, driving demand for respiratory medications. Thus, these factors will propel the upper respiratory tract infection treatment market in the region during the forecast period.
The outbreak of COVID-19 affected all countries in North America, especially the US and Canada, which negatively affected the upper respiratory tract infection therapeutic market in the region in 2020. However, in 2021, the initiation of large-scale vaccination drives?lifted the lockdown and travel restrictions, which led to the resumption of business activities. In addition to that, the COVID-19 pandemic has heightened awareness of respiratory health, potentially leading to increased attention on respiratory care, research, and management. Thus, this is expected to boost the growth of the upper respiratory tract infection treatment market in North America during the forecast period.
Buy Now Full Report and Discover More
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 14 market companies, including:
AstraZeneca Plc: The company offers upper respiratory tract and immunolofy treatment that care for patients, moving beyond symptom control to disease modification, remission and, one day cure.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
Rising demand for over-the-counter drugs is the key factor driving market growth. Patients with colds and coughs often avoid seeing a healthcare professional because the infection can be self-treated with over-the-counter medications. Nasal decongestants such as Afrin (oxymetazoline nasal), Neo-Synephrine (phenylephrine nasal), and Sudafed PE (phenylephrine oral) are some of the over-the-counter drugs that help unclog congested nose.
Moreover, in the case of allergic rhinitis, over-the-counter pills such as Claritin, Alavert, Astelin, and Astepro do not require a written prescription from a healthcare professional and can be directly purchased from a pharmacy. Thus, rising demand for OTC drugs will have a positive impact on the growth of the global upper respiratory tract infection treatment market during the forecast period.
The development of drug-delivery devices to treat upper respiratory tract infections is a primary trend shaping market growth. The development of drug-delivery devices to treat upper respiratory tract infection therapeutic will accelerate market growth. For example, Intersect ENT Inc. (Intersect ENT) is developing a novel device known as ASCEND, an investigational drug-coated sinus balloon. It is designed to deliver corticosteroids directly into sinuses at the time of dilation.
Likewise, Intersect ENTs PROPEL products are the first and only dissolvable implants designed to release mometasone furoate and are approved by the US FDA. PROPEL Contour is indicated for the frontal and maxillary sinuses and PROPEL Mini is indicated for the ethmoid and frontal sinuses. ThusThereforethe development of drug-delivery devices to treat upper respiratory tract infections will propel the growth of the market during the forecast period.
Side effects of NSAIDs is a challenge that affects market growth. NSAIDs are used to treat upper respiratory tract infections therapeutically. However, these drugs are associated with side effects, which can pose a challenge to the market. NSAIDs such as aspirin, ibuprofen, and naproxen are used to treat the common cold. Common side effects of ibuprofen include stomach upset, mild heartburn, nausea, vomiting, bloating, gas, diarrhea, and constipation.
In addition, NSAIDs can cause an increased risk of adverse gastrointestinal events, including bleeding, ulceration, and perforation of the stomach or intestines. Elderly patients with peptic ulcers are at a high risk of serious gastrointestinal events. Therefore, the side effects of NSAIDs have led to a decrease in patient compliance, which may impede market growth during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Upper Respiratory Tract Infection Treatment Market Customer Landscape
The upper respiratory tract infection treatment market report forecasts market growth by revenue at global, regional & country levels and analyzes the latest trends and growth opportunities from 2018 to 2028.
|
Upper Respiratory Tract Infection Treatment Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
170 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.21% |
|
Market growth 2024-2028 |
USD 2,661.15 million |
|
Market structure |
Concentrated |
|
YoY growth 2023-2024(%) |
3.46 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 47% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AstraZeneca Plc, CSL Ltd., GlaxoSmithKline Plc, MD Total Care LLC., Medtronic Plc, Merck and Co. Inc., Novartis AG, Parkway Holdings Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, Teva Pharmaceutical Industries Ltd., The Cleveland Clinic Foundation, and Yashoda Hospitals |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Get the report (PDF) sent to your email within minutes.
